Laidlaw Capital Markets served as Financial Advisor on the $115,000,000 Follow-On Offering for EyePoint Pharmaceuticals
The Team at Laidlaw Capital Markets is pleased to have acted as Financial Advisor on the $115,000,000 Follow-On Offering, alongside Guggenheim and Cowen. This is the third transaction Laidlaw has been a part of with Read More...
Defiance ETFs LLC Rings The Closing Bell®
Laidlaw was proud to attend the closing bell ceremony at the NYSE yesterday. Defiance ETFs LLC is the first 5G ETF (NYSE Arca: FIVG) Alex Shtaynberger, Richard Calhoun and Keith Hassan from Laidlaw attended and were Read More...
Laidlaw served as Co-Manager on the $90mm Ziopharm Oncology (ZIOP) Follow-On Offering
Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies, who was Sole-Book Runner on the transaction. See full Press Read More...
Stay In Touch